One year follow-up study on olanzapine in the treatment of patients with first-episode schizophrenia

ZHANG Hongxia,JIANG Kaida,SHEN Xiaoling,TANG Wenzhong,YANG Xiaomin

DOI: https://doi.org/10.3969/j.issn.1002-0152.2007.08.003

2007-01-01

Abstract:Objective To explore the long-term effectiveness of olanzapine in the treatment of patients with first-episode schizophrenia,meanwhile to evaluate the adverse events.Methods It was a one-year follow-up study with integrated case management and naturalistic observation.One hundred and thirty-six patients of first-episode schizophrenia were included.Patients met ICD-10 criteria for schizophrenia or schizophreniform disorder and were treated with olanzapine,the dose of which was not fixed.Clinical status was assessed with the Positive and Negative Syndrom Scale(PANSS)and the Treatment Emergent Symptom Scale(TESS).Response was defined as improvement in PANSS total score of ≥50%.Results The response rates at the end of 2,3,6,8,12 months were 50%(65/129),57%(71/125),63%(70/69),71%(73/103),75%(70/93),respectively.There were 101 patients who achieved response,and 17 of whom relapsed.Forty-three patients only completed partial follow-up assessments,so the drop-out rate was 31.6%.The mean time to the discontinuation was(9.7±3.8)months(range:1~12 months).The adverse events reported in ≥10% of patients were weight gain,somnolence,constipation,dry mouth,akathisia,tremor,sedation,dizziness and blurred vision.Conclusions Olanzapine was effective for patients with first-episode schizophrenia,yet the adverse events such as weight gain must be considered.